News | May 08, 2024
AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Demonstrate significant bleed reduction in hemophilia A and B
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Subscribe To Our Newsletter & Stay Updated
